Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

Orit Freedman; Eitan Amir; George Dranitsaris; Julie Napolskikh; Ritu Kumar; Michael Fralick; Stephen Chia; Teresa Petrella; Susan Dent; Katia Tonkin; Imran Ahmad; Daniel Rayson; Mark Clemons

doi:10.1007/s10549-009-0452-8

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

Orit Freedman, Eitan Amir, George Dranitsaris, Julie Napolskikh, Ritu Kumar, Michael Fralick, Stephen Chia, Teresa Petrella, Susan Dent, Katia Tonkin, Imran Ahmad, Daniel Rayson, Mark Clemons

科研成果: 期刊稿件 › 文章 › 同行评审

8 引用（Scopus）

源语言	英语
页（从-至）	377-383
页数	7
期刊	Breast Cancer Research and Treatment
卷	118
期	2
DOI	https://doi.org/10.1007/s10549-009-0452-8
出版状态	已出版 - 11月 2009
已对外发布	是

!!!ASJC Scopus Subject Areas

肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s10549-009-0452-8

其它文件与链接

引用此

@article{5752920304e34edca7bcf1f1068b1a3b,

title = "Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients",

author = "Orit Freedman and Eitan Amir and George Dranitsaris and Julie Napolskikh and Ritu Kumar and Michael Fralick and Stephen Chia and Teresa Petrella and Susan Dent and Katia Tonkin and Imran Ahmad and Daniel Rayson and Mark Clemons",

note = "Funding Information: Acknowledgments Funding for this study was provided from an unrestricted grant in aid from AstraZeneca Canada.",

year = "2009",

month = nov,

doi = "10.1007/s10549-009-0452-8",

language = "English",

volume = "118",

pages = "377--383",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

AU - Freedman, Orit

AU - Amir, Eitan

AU - Dranitsaris, George

AU - Napolskikh, Julie

AU - Kumar, Ritu

AU - Fralick, Michael

AU - Chia, Stephen

AU - Petrella, Teresa

AU - Dent, Susan

AU - Tonkin, Katia

AU - Ahmad, Imran

AU - Rayson, Daniel

AU - Clemons, Mark

N1 - Funding Information: Acknowledgments Funding for this study was provided from an unrestricted grant in aid from AstraZeneca Canada.

PY - 2009/11

Y1 - 2009/11

UR - http://www.scopus.com/inward/record.url?scp=70350221678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350221678&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0452-8

DO - 10.1007/s10549-009-0452-8

M3 - Article

C2 - 19551499

AN - SCOPUS:70350221678

SN - 0167-6806

VL - 118

SP - 377

EP - 383

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此